SGMO SEC Filings Report for 11/13/2024
SEC Filings - Sangamo Therapeutics, Inc.
SEC Filings ; Nov 12, 2024, 10-Q · Quarterly report which provides a continuing view of a company's financial position. Quarterly Filings.
SANGAMO THERAPEUTICS, INC - EDGAR Entity Landing Page
SANGAMO THERAPEUTICS, INC SGMO on Nasdaq ; 8-K (current reports). October 4, 2024 - 8-K: Current report ; 10-K (annual reports) and 10-Q (quarterly reports).
Sangamo Therapeutics, Inc. Common Stock (SGMO) SEC Filings
Nasdaq provides company's SEC filings, which are financial statements and reports filed electronically with the US Securities and Exchange Commission (SEC) by ...
SGMO SEC Filings Report for 11/13/2024 | News Quantified
Discover the SEC EDGAR filings impact for SGMO. Form Sc 13g/A Sangamo Therapeutics Filed By Vanguard Group Inc.
Investors - Sangamo Therapeutics, Inc.
November 13, 2024, $2.44, 9,913,978, $2.25, $2.82, $2.25. Financials & SEC Filings. Current Financials. Cash Flow · Current Financials. Snapshot · Current ...
Sangamo Therapeutics (SGMO) SEC Filings & 10K Form - MarketBeat
Recent Sangamo Therapeutics SEC Filings ; 08/27/2024 3:36 PM, Macrae Sandy (Reporting) Sangamo Therapeutics (Issuer), Form 4. Statement of changes in beneficial ...
Sangamo Therapeutics reports progress in gene therapies
Published 11/13/2024, 06:18 AM. Earnings call: Sangamo Therapeutics reports progress in gene therapies ... and reports that Sangamo makes from time-to-time with the SEC. The forward-looking ...
SGMO 10-K & SEC Filings - Yahoo Finance
SGMO : 10-K : Periodic Financial Reports ; Item 1. Business ; Item 1A. Risk Factors ; Item 1B. Unresolved Staff Comments.
Sangamo Therapeutics Inc. SEC Filings - SGMO - MarketWatch
Sangamo Therapeutics Inc. SEC filings breakout by MarketWatch. View the SGMO U.S. Securities and Exchange Commission reporting information.
Sangamo Therapeutics Reports Recent Business Highlights and ...
Announced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in ...
EDGAR Filing Documents for 0001628280-24-042308 - SEC.gov
SEC Accession No ; 1, 8-K · sgmo-20241004.htm iXBRL, 8-K · 37599 ; 2, EX-99.1, section205verifiedpetiti.htm, EX-99.1, 40650.
SGMO - Sangamo Therapeutics, Inc. Stock - Stock Price, Institutional ...
We present 13D/G filings separately from the 13F filings because of the different treatement by the SEC. 13D/G filings can be filed by groups of investors (with ...
SGMO Stock Impact Report for 11/13/2024 | News Quantified
Discover the stock impact of the latest SGMO news. Sangamo Therapeutics Reports Recent Business Highlights And Third Quarter 2024.
Sangamo Therapeutics, Inc. Common Stock (SGMO) Earnings
Common Stock is expected* to report earnings on 11/12/2024 after market close. The report will be for the fiscal Quarter ending Sep 2024. According to Zacks ...
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights
Nov 13, 2024. Summary ... The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and ...
S-3 Table of Contents As filed with the Securities and Exchange Commission on November 13, 2024 Registration No. enGene Holdings Inc. enGene Holdings Inc. - S-3 ...
A copy of the Section 205 Application in the form filed with the Court of Chancery is attached as Exhibit 99.1 to this Current Report on Form 8-K. Concurrently ...
Sangamo Therapeutics, Inc. (SGMO) - Yahoo Finance
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results ... As of 11/13/2024. Market Cap. 508.06M. Enterprise Value.
Barclays Raises Sangamo Therapeutics (NASDAQ:SGMO) Price ...
Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) had its ... Check stock news, ratings, SEC filings, and more. Stock Ideas and ...
Sangamo Therapeutics Reports on Pfizer's Announcement of ...
SANGAMO THERAPEUTICS REPORTS ON PFIZER'S ANNOUNCEMENT OF POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF HEMOPHILIA A GENE THERAPY CANDIDATE.